MedTrace Logo

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

NCT01171105 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2015-01-28

No results posted yet for this study

Summary

1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after multiple oral doses.
2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves your body and how your body acts on the study drug) of AZD5213 in your blood and urine.

Conditions

  • Healthy

Interventions

DRUG

AZD5213

oral solution, multiple ascending doses

DRUG

Placebo to AZD5213

Sponsors & Collaborators

Principal Investigators

  • David Mathews, MD · Quintiles, 6700 W. 115th Street, Overland Park, KS 66211

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01171105 on ClinicalTrials.gov